San Raffaele
| イタリア | トルコ | オーストリア | |
| 膵臓がん化学療法 | から $10,000 | から $1,500 | から $10,000 |
Bookimedは膵臓がん化学療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで膵臓がん化学療法代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。膵臓がん化学療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。膵臓がん化学療法の旅路でお一人になることはありません。
Standard chemotherapy protocols in Italy for pancreatic cancer follow Italian Medical Oncology Association (AIOM) guidelines. Fit patients typically receive intensive regimens like PAXG or FOLFIRINOX. For elderly or less fit patients, Gemcitabine combined with nab-paclitaxel or Gemcitabine monotherapy is the primary clinical standard for metastatic and adjuvant care.
Bookimed Expert Insight: The PAXG regimen is a unique Italian innovation that shows superior event-free survival in neoadjuvant settings compared to mFOLFIRINOX. Patients seeking this specific protocol should look at IRCCS-accredited research hospitals like San Raffaele in Milan. These institutions often provide faster access to the latest AIFA-approved combinations than general public hospitals.
Patient Consensus: Patients often emphasize starting FOLFIRINOX as early as possible while physical fitness is high. Many note that major centers in Milan offer faster treatment initiation compared to other European systems.
Patients should plan to stay in Italy for 7 to 14 days per chemotherapy cycle. This timeframe allows for treatment, recovery, and essential monitoring. Major post-operative care requires a longer commitment. Expect 2 to 6 weeks in the country before safe air travel is permitted.
Bookimed Expert Insight: Research hospitals like San Raffaele in Milan manage over 52,000 operations annually. Their high patient volume suggests efficient recovery protocols. These centers often combine research with treatment. This helps patients reach travel-readiness milestones faster than smaller facilities.
The most experienced Italian centers for pancreatic cancer chemotherapy and multidisciplinary care are located in Milan and Verona. Ospedale San Raffaele and Istituto Europeo di Oncologia (IEO) lead in oncology research. These facilities utilize specialized Tumor Boards to coordinate systemic treatments and surgical interventions.
Bookimed Expert Insight: San Raffaele in Milan performs over 52,000 operations annually and serves 300,000 patients. This massive scale allows their oncology department to manage rare pancreatic subtypes. Their status as an IRCCS ensures patients receive therapies based on the latest ministerial research standards. Use this high volume as a proxy for specialized technical skill.
Patient Consensus: Patients emphasize seeking centers treating at least 20 cases annually for better outcomes. Many recommend checking trial enrollment dates early to avoid missing cutting-edge treatment windows.
Italian pancreatic cancer guidelines (AIOM) classify neoadjuvant chemotherapy as the mandatory standard for borderline resectable (BRPC) and locally advanced (LAPC) cases. This preoperative approach aims to shrink tumors near major vessels, treat micrometastatic disease early, and increase the probability of successful R0 surgical resections.
Bookimed Expert Insight: While standard protocols favor surgery for resectable cases, high-volume Italian centers like Ospedale San Raffaele increasingly apply neoadjuvant therapy more broadly. Their IRCCS research status allows patients access to intensive trials like CASSANDRA, which may explain why Italian R0 resection rates often exceed global averages.
Patient Consensus: Patients emphasize that neoadjuvant treatment requires stamina for 3 to 6 months of intensive chemotherapy. Many recommend seeking a second opinion if a surgeon pushes for immediate surgery without considering preoperative tumor shrinkage.